XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.4
Note C - Revenues
9 Months Ended
Dec. 28, 2025
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

NOTE C – REVENUES

 

The Company’s disaggregated revenues for the thirteen and thirty-nine weeks ended December 28, 2025 and December 29, 2024 are as follows (in thousands): 

 

   

Thirteen weeks ended

   

Thirty-nine weeks ended

 
   

December 28, 2025

   

December 29, 2024

   

December 28, 2025

   

December 29, 2024

 
                                 

Branded Products

  $ 23,749     $ 21,099     $ 81,871     $ 71,781  

Company-owned restaurants

    1,646       1,804       11,256       11,351  

License royalties

    7,385       7,105       28,993       29,517  

Franchise royalties

    906       897       3,045       2,944  

Franchise fees

    114       94       327       294  

Advertising fund revenue

    512       520       1,505       1,508  

Total revenues

  $ 34,312     $ 31,519     $ 126,997     $ 117,395  

 

The following table disaggregates revenues by primary geographical market (in thousands):

 

   

Thirteen weeks ended

   

Thirty-nine weeks ended

 
   

December 28, 2025

   

December 29, 2024

   

December 28, 2025

   

December 29, 2024

 
                                 

United States

  $ 33,480     $ 30,659     $ 124,275     $ 114,419  

International

    832       860       2,722       2,976  

Total revenues

  $ 34,312     $ 31,519     $ 126,997     $ 117,395  

 

Contract balances

 

The following table provides information about contract liabilities from contracts with customers (in thousands):

 

   

December 28, 2025

   

March 30, 2025

 

Deferred franchise fees (a)

  $ 773     $ 1,006  

Deferred revenues, which are included in

               

“Accrued expenses and other current liabilities” (b)

  $ 250     $ 1,392  

 

 

(a)

Deferred franchise fees of $216 and $557 as of December 28, 2025 and $309 and $697 as of March 30, 2025 are included in Deferred franchise fees – current and long term, respectively.

 

(b)

Includes $250 of deferred advertising fund revenue as of December 28, 2025 and $892 of deferred license royalties and $500 of deferred advertising fund revenue as of March 30, 2025.

 

Significant changes in deferred franchise fees are as follows (in thousands):

 

   

Thirty-nine weeks ended

 
   

December 28, 2025

   

December 29, 2024

 

Deferred franchise fees at beginning of period

  $ 1,006     $ 1,226  

New deferrals due to cash received and other

    94       94  

Revenue recognized during the period

    (327 )     (294 )

Deferred franchise fees at end of period

  $ 773     $ 1,026  

 

Significant changes in deferred revenues are as follows (in thousands):

 

   

Thirty-nine weeks ended

 
   

December 28, 2025

   

December 29, 2024

 

Deferred revenues at beginning of period

  $ 1,392     $ 1,375  

New deferrals due to cash received and other

    500       500  

Revenue recognized during the period

    (1,642 )     (1,625 )

Deferred revenues at end of period

  $ 250     $ 250  

 

Anticipated future recognition of deferred franchise fees

 

The following table reflects the estimated franchise fees to be recognized in the future related to performance obligations that are unsatisfied at the end of the period (in thousands):

 

   

Estimate for fiscal year

 

2026 (a)

  $ 74  

2027

    191  

2028

    100  

2029

    72  

2030

    52  

Thereafter

    284  

Total

  $ 773  

 

 

(a)

Represents franchise fees expected to be recognized for the remainder of the 2026 fiscal year, which includes international development fees expected to be recognized over the duration of one year or less. Amount does not include $327 of franchise fee revenue recognized for the thirty-nine weeks ended December 28, 2025.

 

We have applied the optional exemption, as provided for under ASC Topic 606 “Revenues from Contracts with Customers,” which allows us to not disclose the transaction price allocated to unsatisfied performance obligations when the transaction price is a sales-based royalty.